Alfonso Duenas-Gonzalez
Overview
Explore the profile of Alfonso Duenas-Gonzalez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
2729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bornstein-Quevedo L, Duenas-Gonzalez A
J Thorac Oncol
. 2025 Feb;
20(2):e19.
PMID: 39914920
No abstract available.
2.
Candelaria M, Cerrato-Izaguirre D, Gutierrez O, Diaz-Chavez J, Aviles A, Duenas-Gonzalez A, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273276
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy worldwide. Molecular classifications have tried to improve cure rates. We prospectively examined and correlated the mutational landscape with the...
3.
Gonzalez-Fierro A, Dominguez-Gomez G, Chavez-Blanco A, Duenas-Gonzalez A
Expert Opin Drug Metab Toxicol
. 2024 Sep;
21(2):133-141.
PMID: 39252168
Introduction: The treatment of advanced cervical cancer is continuously developing. There is a critical need to explore new treatment options to improve cure rates and make treatment more affordable. Despite...
4.
Salamanca-Ortiz H, Dominguez-Gomez G, Chavez-Blanco A, Ortega-Bernal D, Diaz-Chavez J, Gonzalez-Fierro A, et al.
Am J Cancer Res
. 2024 Jul;
14(6):3068-3082.
PMID: 39005694
Lymphoma is a disease that affects countless lives each year. In order to combat this disease, researchers have been exploring the potential of DNMTi and HDACi drugs. These drugs target...
5.
Duenas-Gonzalez A, Gonzalez-Fierro A, Bornstein-Quevedo L, Gutierrez-Delgado F, Kast R, Chavez-Blanco A, et al.
Expert Rev Anticancer Ther
. 2024 Jun;
24(8):665-677.
PMID: 38913911
Introduction: The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is...
6.
Robles-Banuelos B, Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, Gonzalez-Fierro A, Duenas-Gonzalez A
Clin Transl Oncol
. 2023 Dec;
26(5):1077-1088.
PMID: 38064014
Drug repurposing of widely prescribed patent-off and cheap drugs may provide affordable drugs for cancer treatment. Nevertheless, many preclinical studies of cancer drug repurposing candidates use in vitro drug concentrations...
7.
Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, Gonzalez-Fierro A, Correa-Basurto J, Duenas-Gonzalez A
Curr Med Chem
. 2023 Jun;
31(22):3265-3285.
PMID: 37287286
Background: Prostate cancer is the most frequently diagnosed malignancy in 112 countries and is the leading cause of death in eighteen. In addition to continuing research on prevention and early...
8.
Gonzalez-Fierro A, Romo-Perez A, Chavez-Blanco A, Dominguez-Gomez G, Duenas-Gonzalez A
Clin Drug Investig
. 2023 Mar;
43(4):227-239.
PMID: 36884210
Therapeutic repurposing emerged as an alternative to the traditional drug discovery and development model (DDD) of new molecular entities (NMEs). It was anticipated that by being faster, safer, and cheaper,...
9.
Arango-Bravo E, Cetina-Perez L, Galicia-Carmona T, Castro-Eguiluz D, Gallardo-Rincon D, Cruz-Bautista I, et al.
Front Oncol
. 2022 Dec;
12:1028291.
PMID: 36530977
Cervical cancer (CC) is tightly related to a low Human Development Index. Mexico is an upper-middle-income country with 126 million inhabitants, and its public health system aims to provide universal...
10.
Duenas-Gonzalez A
Expert Opin Pharmacother
. 2022 Jun;
24(1):73-81.
PMID: 35653267
Introduction: From a therapeutic standpoint, invasive cervical cancer can be designated as early, locally advanced, and advanced stages. Systemic treatment remains the primary therapeutical modality for advanced cervical cancer patients...